NSCLC
-
New algorithm calculates drug synergy; initial tests involve melanoma, lung cancer
Drug combinations used for the treatment of non-small-cell lung cancer (NSCLC) and melanoma aren’t as effective as they could be. Oncologists haven’t had the right tools to predict drug interactions, other than in costly clinical trials. That could change with a new algorithm developed by a cross-disciplinary Vanderbilt University team… Read MoreFeb 20, 2019